We come together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease.
On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies.
We continuously seek to understand the diverse perspectives of rare patients to courageously forge new paths that can make a difference in their lives and provide hope for today and tomorrow.
We are committed to broad access for our FDA-approved therapies, and we provide personalized clinical support services through the Total Care Hub.
We are dedicated to staying informed and engaged on topics that may impact the rare disease community, featuring community members and sharing what we learn. Find info at our Pathfinder.
Ernst & Young today announced that our CEO Eric Dube has been named an Entrepreneur of the Year 2022 Pacific Southwest Award winner! This prestigious award recognizes exemplary leaders who lift up their employees and their communities and are focused on creating a better world for all. A panel of independent judges selected 13 winners out of the 40 finalists who were eligible for the award.
SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced presentations including baseline characteristics for patients enrolled in the ongoing pivotal Phase 3 PROTECT and DUPLEX studies of sparsentan in IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS), respectively, at the 59th European Renal Association (ERA) Congress. The Company and its collaborators will also present nonclinical data examining the renal protective effects of sparsentan compared to controls. ERA is being held live in Paris, France, and virtually May 19-22, 2022.
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review of its New Drug Application (NDA) under Subpart H for accelerated approval of sparsentan for the treatment of IgA nephropathy (IgAN).
In the spring of 2020, after a hike with her husband and kids, Stephanie’s legs swelled unfathomably. She took a video of herself pressing her fingers into her legs, showing how her fingers would sink into the skin.
SAN DIEGO, May 5, 2022 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its first quarter 2022 financial results and provided a corporate update.
Retrophin is now Travere Therapeutics.
© 2022 Travere Therapeutics, Inc. All rights reserved. For US audiences. Chenodal®, Cholbam® and Total Care HUB® are registered trademarks of Travere Therapeutics, Inc. Thiola® and Thiola EC® are registered trademarks of Mission Pharmacal Company.
Travere Therapeutics Provides Regulatory Updates on its Development Programs
NewsSAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today provided regulatory updates for its sparsentan programs in IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS), as well as its pegtibatinase program for classical homocystinuria (HCU).
Read the full press release >